在T细胞免疫治疗中CD28和PD-1之间的相互作用
Zuhayr Jafri1, Jingwen Zhang1, Connor H O'Meara2
1Vascular Biology and Translational Research, Department of Pathology, School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Vascular pharmacology
|December 29, 2024
概括
针对固体瘤的免疫检查点疗法因T细胞耗尽而面临阻力. 准辅助刺激受体CD28显示出克服这种疲劳并增强抗PD-1疗法的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症免疫疗法癌症免疫疗法
背景情况:
- 针对PD-1/PD-L1通路的免疫检查点抑制剂已经改变了固体瘤治疗.
- T细胞耗尽是抗PD-1疗法耐药性的主要机制,导致患者反应不足最佳.
研究的目的:
- 在T细胞免疫治疗中探索PD-1和CD28信号传递之间的复杂相互作用.
- 阐明CD28信号转录如何调节T细胞耗尽.
- 审查针对CD28的临床策略,包括过去的挑战和最近的进展.
主要方法:
- 对PD-1/PD-L1和CD28信号通路的现有文献的审查.
- 对T细胞耗尽机制在免疫治疗反应中的分析.
- 检查临床试验数据和研究CD28向疗法的研究.
主要成果:
- CD28共刺激信号可以抵消T细胞耗尽.
- CD28影响PD-1信号传递,这表明在免疫治疗中具有协同作用的潜力.
- CD28在T细胞耗尽的转录调节中发挥作用.
结论:
- CD28代表了一个有希望的补充目标,以提高PD-1/PD-L1阻断疗法的疗效.
- 通过CD28调制克服T细胞疲劳对于改善癌症患者的治疗结果至关重要.
- 未来的CD28向剂的临床开发具有癌症免疫治疗的巨大潜力.
相关概念视频
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
T Cell Activation and Clonal Selection
655
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
655
T Cell Types and Functions
947
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
947


